Phase 1 SAD study of peresolimab in healthy Japanese and non-Japanese participants

Phase 1, randomised, double-blind trial of peresolimab in rheumatoid arthritis (RA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Jun 2022; status: completed.